Natera Inc
NTRA
Market Cap$23.47B
Close$
Earnings Call Q1 2025
May 8, 2025 - AI Summary
Strong Revenue Growth: Natera reported Q1 2025 revenue of $502 million, a 37% year-over-year increase from $368 million in Q1 2024. This growth is driven by a remarkable uptick in volume, with 855,000 units processed this quarter, reflecting exceptional performance across all segments, particularly women's health and oncology.
Record Volume and ASP Improvement: Signatera clinical volumes grew by 52% year-over-year, with a significant sequential increase of 16,500 units compared to Q4 2024. Average selling prices (ASP) for Signatera surpassed $1,100, benefiting from improved reimbursement coverage, particularly in Medicare Advantage.
Revised Revenue Guidance: The company raised its 2025 revenue guidance by $70 million at the midpoint, projecting revenues to be in the range of $1.94 billion to $2.02 billion. This reflects a strong outlook of approximately 26% revenue growth year-over-year, excluding true-ups, indicating sustained market demand and operational efficiencies.
Exclusive for Stockcircle Pro members
Sign up
$-160.91
193.6% downside
Current Fair Value
193.6% downsideOvervalued by 193.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.47 Billion |
|---|---|
| Enterprise Value | $22.74 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.53 |
| Beta | 1.74 |
| Outstanding Shares | 134,750,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -122.04 |
|---|---|
| PEG | 12442.82 |
| Price to Sales | 13.22 |
| Price to Book Ratio | 19.1 |
| Enterprise Value to Revenue | 12.42 |
| Enterprise Value to EBIT | -105.14 |
| Enterprise Value to Net Income | -120 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Natera Inc
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operat...